Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hydroxyprogesterone Caproate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Commissioner and Chief Scientist Announce Decision to Withdraw Approval of Makena
Details : Makena (hydroxyprogesterone caproate) is a synthetic progestin. The drug was approved to reduce the risk of preterm birth in women pregnant with one baby who have a history of spontaneous preterm birth. It has been withdrawn and cannot lawfully be distri...
Brand Name : Makena
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 06, 2023
Lead Product(s) : Hydroxyprogesterone Caproate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aclidinium Bromide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Duaklir (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) are inhaled respiratory medicines used for the maintenance treatment of COPD. Eklira is a LAMA and Duaklir is a combination therapy that contains both a LAMA and a long-acting beta2...
Brand Name : Duaklir
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 25, 2022
Lead Product(s) : Aclidinium Bromide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Hydroxyprogesterone Caproate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Covis Pharma Provides Update on FDA Public Hearing for Makena
Details : Makena, also referred to as 17 α-hydroxyprogesterone caproate, 17-OHPC, 17-HPC, or 17P, is the only FDA-approved treatment to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
Brand Name : Makena
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 14, 2022
Lead Product(s) : Hydroxyprogesterone Caproate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Recipient : AstraZeneca
Deal Size : $270.0 million
Deal Type : Acquisition
Covis Completes Acquisition of Global Respiratory Portfolio of Two Medicines from AstraZeneca
Details : Under the terms of the Acquisition agreement, Covis Pharma has completed the acquisition of Eklira® (aclidinium bromide), known as Tudorza® in US and marketed as Bretaris® in some countries, and Duaklir® (aclidinium bromide/formoterol), marketed as B...
Brand Name : Eklira
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 05, 2022
Lead Product(s) : Aclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Recipient : AstraZeneca
Deal Size : $270.0 million
Deal Type : Acquisition
Lead Product(s) : Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Details : Covis has entered into an Exclusive Promotion and Distribution Agreement with Novartis Pharmaceuticals Canada, whereby Covis has been appointed as Novartis’ exclusive partner to promote and distribute PrSeebri® Breezhaler® and PrUltibro® BreezhalerÂ...
Brand Name : Seebri Breezhaler
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 05, 2022
Lead Product(s) : Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Aclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Recipient : AstraZeneca
Deal Size : $270.0 million
Deal Type : Agreement
AstraZeneca to Transfer Global Rights For Eklira and Duaklir to Covis Pharma
Details : Covis Pharma acquired the rights of Eklira (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol), inhaled respiratory medicines used for the maintenance treatment of COPD from AstraZeneca.
Brand Name : Eklira
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 01, 2021
Lead Product(s) : Aclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Recipient : AstraZeneca
Deal Size : $270.0 million
Deal Type : Agreement
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Norgine
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ciraparantag is a novel small, water-soluble molecule being investigated for reversal of anticoagulation induced by direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH).
Brand Name : PER977
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 04, 2021
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Norgine
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Hydroxyprogesterone Caproate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EPPPIC Study Reaffirms 17-OHPC for Reducing Early Preterm Birth in High-Risk, Singleton Pregnancies
Details : The publication presents the results of a meta-analysis of individual participant data from five trials examining injectable 17-alpha hydroxyprogesterone (17-OHPC), also referred to as MakenaÃ’ or generic alternatives.
Brand Name : Makena
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 26, 2021
Lead Product(s) : Hydroxyprogesterone Caproate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Hydroxyprogesterone Caproate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : FDA’s Notice of Opportunity for a Hearing regarding the Agency’s proposal to withdraw approval for Makena also referred to as 17-OHPC, to reduce preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm bir...
Brand Name : Makena
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 14, 2020
Lead Product(s) : Hydroxyprogesterone Caproate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The published preclinical data demonstrate that ciraparantag has several key attributes including its ability to reverse the anticoagulant effect of apixaban, rivaroxaban, edoxaban, dabigatran, and LMWH.
Brand Name : PER977
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 19, 2020
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?